A
What happened
India's obesity drug market has expanded rapidly, growing nearly ten-fold to over ₹1,000 crore in five years. This growth is driven by rising lifestyle diseases and new blockbuster injections from global leaders like Novo Nordisk and Eli Lilly. The upcoming launch of low-cost generics in 2026 is expected to increase affordability and access, broadening the market beyond urban elites. This shift highlights a major change in pharmaceutical care for chronic diseases in India.
★
Key insights
-
1
Market Growth: The domestic anti-obesity market has grown nearly ten-fold in five years, signaling strong momentum.
-
2
Impact of Generics: Entry of cheaper generics is expected to reduce prices by about 60%, intensifying competition and expanding access.
-
3
Pharma Strategies: Companies are expanding outreach and partnerships to improve access beyond major cities.
Takeaways
The expansion of obesity drug therapies, supported by innovation and affordability, marks a significant transformation in India's pharmaceutical industry addressing chronic lifestyle diseases.